Humacyte (NASDAQ:HUMA) Earns “Buy” Rating from D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Other research analysts also recently issued research reports about the company. Barclays assumed coverage on Humacyte in a research note on Wednesday, August 27th. They set an “overweight” rating and a $3.50 target price for the company. BTIG Research dropped their price objective on shares of Humacyte from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, October 13th. UBS Group set a $6.00 price target on shares of Humacyte in a report on Monday, October 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, October 8th. Finally, HC Wainwright lowered their price objective on Humacyte from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.29.

Humacyte Price Performance

HUMA traded up $0.08 on Thursday, hitting $1.25. 716,485 shares of the stock were exchanged, compared to its average volume of 4,318,350. The firm has a market capitalization of $197.17 million, a price-to-earnings ratio of -5.40 and a beta of 1.88. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. Humacyte has a 12 month low of $1.12 and a 12 month high of $6.77. The business has a 50-day moving average of $1.61 and a two-hundred day moving average of $1.94.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. The firm had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.92 million. Sell-side analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Humacyte

A number of institutional investors have recently added to or reduced their stakes in the company. Lazari Capital Management Inc. bought a new position in shares of Humacyte during the 2nd quarter worth approximately $27,000. Truist Financial Corp bought a new position in Humacyte in the 3rd quarter valued at $28,000. Prudential Financial Inc. bought a new stake in shares of Humacyte during the 2nd quarter worth $28,000. Financial Advisors Network Inc. purchased a new position in shares of Humacyte in the 2nd quarter worth about $28,000. Finally, Equitable Holdings Inc. purchased a new stake in Humacyte during the third quarter worth about $29,000. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.